Your browser doesn't support javascript.

BVS del Sindicato Médico del Uruguay

Portal de Búsqueda de la BVS

Home > Búsqueda > ()
XML
Imprimir Exportar

Formato de exportación:

Exportar

Email
Adicionar mas contactos
| |

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.

Najafzadeh, Mehdi; Andersson, Karin; Shrank, William H; Krumme, Alexis A; Matlin, Olga S; Brennan, Troyen; Avorn, Jerry; Choudhry, Niteesh K.
Ann Intern Med ; 162(6): 407-19, 2015 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-25775313

BACKGROUND:

New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive.

OBJECTIVE:

To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy.

DESIGN:

Discrete-event simulation. DATA SOURCES Published literature. TARGET POPULATION Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON Lifetime. PERSPECTIVE Societal. INTERVENTION Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME

MEASURES:

Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE

ANALYSIS:

Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY

ANALYSIS:

Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week.

LIMITATION:

Data are lacking on real-world effectiveness of new treatments and some prices.

CONCLUSION:

From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE CVS Health.